CD79A and nasopharyngeal carcinoma: A combination of ENBA1-IgA with five other antibodies (BLLF3-IgA, BLRF2-IgA, BLRF2-IgG, BDLF1-IgA, BDLF1-IgG) resulted in a similar sensitivity at 95% specificity to diagnose NPC as the known biomarker combination, VCA-IgA and ENBA1-IgA (Table 1).